In addition, the researchers found that melanoma tumor cells can change their appearance by switching various genes on and off, making the malignant cells a stealthy, shape-shifting target for researchers seeking new treatments, according to a team led by Sean Morrison, director of the U-M Center for Stem Cell Biology.
Both findings fly in the face of the cancer stem cell model, which states that a handful of rare stem cells drive the formation, growth and progression of malignant tumors in many cancers. Some supporters of the model have suggested that melanoma might be more effectively treated by taking aim specifically at these rare cancer stems cells, rather than attempting to eliminate all melanoma cells.
|Dr. Timothy Johnson|
But after conducting an exhaustive search for this elusive sub-population of tumor-forming melanoma cell, the U-M team concluded that it probably does not exist. The researchers analyzed 44 sub-populations of human melanoma cells, and all 44 had a similar ability to form tumors when transplanted into mice.
“Some have suggested that melanoma follows a cancer stem cell model in which only rare cells are able to proliferate extensively and form new tumors,” said Morrison, a Howard Hughes Medical Institute investigator.
“Our results suggest that most melanoma cells are capable of driving disease progression and that it won’t be possible to cure patients by targeting rare sub-populations of cells,” Morrison said. “We think you need to kill all the cells.”
The team’s findings will be published Nov. 16 in the journal Cancer Cell. The first authors of the paper are Elsa Quintana of the U-M Center for Stem Cell Biology, based at the Life Sciences Institute, and Mark Shackleton, formerly with the Morrison lab and now at the Peter MacCallum Cancer Center in Melbourne, Australia.
The study found that tumor-forming melanoma cells have the ability to throw a genetic switch that changes the types of proteins expressed on the cells’ surface. The study is the first to present evidence for this type of pervasive “phenotypic plasticity” among melanoma cells from patients.
Patterns of surface proteins are used to identify different cell types and are commonly called cell surface markers.
“The fact that these markers are turned on and off by melanoma cells raises the possibility that melanoma cells may also turn on and off genes that regulate clinically important characteristics like drug resistance and metastatic ability,” Morrison said. “The ability to transition between various states may make melanoma more difficult to treat.”
The authors stress that while their results argue against a cancer stem cell model for melanoma, their findings do not invalidate the model. In fact, certain leukemias and other cancers appear to follow the model.
“It will be critical to determine which cancers follow a stem cell model and which do not, so therapies designed to target rare sub-populations of cells are not inappropriately tested in patients whose disease is driven by many diverse cancer cells,” Quintana said.
The cancer stem cell model assumes that cells differing in marker expression also differ in function, and that only a very small subset of cancer cells displaying the critical marker pattern—less than 1 percent of cancer cells—can form tumors. The model proposes that most of the cancer cells that compose tumors have little or no capacity to proliferate or to contribute to disease progression.
“The cancer stem cell model says that tumor cells are organized hierarchically, and that only the cells at the top of the hierarchy form tumors. Cells at the bottom of the hierarchy can’t,” Morrison said. However, the Morrison laboratory was unable to find any subset of melanoma cells that lacked the ability to form tumors.
“In our model, all these cells can form tumors,” he said. “And they’re phenotypically different from each other not because they’re hierarchically organized but because they’re just turning these surface markers on and off.”
The U-M team found that all tumor-forming melanoma cells gave rise to progeny with a variety of marker patterns, and that all of those sub-populations retained the ability to form tumors. The marker changes appeared to be reversible, rather than being associated with a transition from tumor-forming to non-tumor-forming states, as the cancer stem cell model would predict.
The Cancer Cell paper follows up on work reported by the Morrison lab in the Dec. 4, 2008, edition of the journal Nature. The Nature article demonstrated that tumor-forming melanoma cells are not rare, as predicted by the cancer stem cell model. The researchers determined that at least one-quarter of melanoma cells have the ability to form new tumors.
Melanoma kills more than 8,000 Americans each year. The human melanoma cells used in this study were provided—with the patients’ permission—from the U-M’s Multidisciplinary Melanoma Program, one of the country’s largest melanoma programs and part of the U-M Comprehensive Cancer Center.
“These new findings significantly advance our understanding of melanoma,” said cutaneous oncologist Dr. Timothy Johnson, director of the U-M melanoma program and a co-author of the Cancer Cell paper.
“This type of groundbreaking discovery achieves our core objective of combining clinical studies with laboratory research to develop new and better treatments for optimal patient care,” Johnson said.
In addition to Morrison, Quintana, Shackleton and Johnson, the paper’s authors are Hannah Foster of the Center for Stem Cell Biology; Dr. Douglas Fullen, associate professor of pathology and associate professor of dermatology at the Medical School; and Dr. Michael Sabel, associate professor of surgery at the Medical School.
The work was supported by the Howard Hughes Medical Institute and the Allen H. Blondy Research Fellowship. The U-M Melanoma Bank was supported by a gift from Lewis and Lillian Becker. Flow cytometry was partially supported by a National Institutes of Health grant to the U-M Comprehensive Cancer Center.
Elsa Quintana was supported by the Marie Curie Outgoing International Fellowship from the European Commission. Mark Shackleton was supported by the Australian National Health and Medical Research Council, the Human Frontiers Science Program, and Australia Post.
Contact: Jim Erickson
Phone: (734) 647-1842